NEW YORK (GenomeWeb) — Predicine said today that it has received CLIA certification for its genomic sequencing lab in Hayward, California.
"CLIA certification is a critical step that enables us to work with liquid and tissue biopsy samples while we scale for full commercial launch this year," Predicine Founder and CEO Shidong Jia said in a statement. "We can now participate in a greater variety of therapeutic clinical trials to provide molecular information about the disease status and therapeutic response of a patient at each clinical decision point … [as well as] partner with pharma clients in companion diagnostic development."
Predicine, which closed a $13.5 million Series A round earlier this year, is developing a proprietary technology for the detection of RNA- and DNA-based genetic alterations in blood samples, while building a pipeline of cancer biomarkers. The company also maintains an R&D facility in China where it markets next-generation sequencing-based liquid biopsy diagnostics for lung cancer and prostate cancer in partnership with CloudHealth Genomics.